Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HAL SKOPICKI

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1346264553
CMS profile
333750
Location
ISLANDIA, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$647.26

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $500.00 2
Abbott Laboratories $136.06 5
E.R. Squibb & Sons, L.L.C. $11.20 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HAL SKOPICKI

NPI 1346264553 · CMS profile ID 333750

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

ISLANDIA, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346264553?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HAL SKOPICKI, NPI 1346264553, CMS profile ID 333750. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346264553?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). HAL SKOPICKI, NPI 1346264553, CMS profile ID 333750. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346264553?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
HAL SKOPICKI, NPI 1346264553, CMS profile ID 333750, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1346264553?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $647.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $11.2012/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728007505 CMS
Abbott Laboratories $21.9412/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746587417 CMS
AstraZeneca Pharmaceuticals LP $250.0008/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735877487 CMS
AstraZeneca Pharmaceuticals LP $250.0008/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736402261 CMS
Abbott Laboratories $47.0405/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746582905 CMS
Abbott Laboratories $20.1805/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746582951 CMS
Abbott Laboratories $23.7403/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746590879 CMS
Abbott Laboratories $23.1602/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746588935 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,139.99 16
PY2020 $647.26 8
PY2021 $12,069.00 12
PY2022 $2,586.05 5
PY2023 $295.23 4
PY2024 $443.71 6
PY2025 $308.21 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $123,059.53 14
PY2024 Principal investigator $131,886.60 14
PY2023 Principal investigator $177,782.25 13
PY2022 Principal investigator $122,194.96 15
PY2021 Principal investigator $219,308.12 45
PY2020 Principal investigator $152,408.74 95
PY2019 Principal investigator $126,188.89 103

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

103 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,049.73 12/31/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 704738947
Principal investigator 1 Boehringer Ingelheim International GmbH $1,203.00 12/13/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703928429
Principal investigator 1 Boehringer Ingelheim International GmbH $103.00 12/11/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703928587
Principal investigator 1 LivaNova USA, Inc. $750.00 12/10/2019 Non-covered Recipient Entity
The Research Foundation of State University of New York
ANTHEM HFrEF No dispute reported 06/30/2026 703215851
Principal investigator 1 Boehringer Ingelheim International GmbH $59.00 12/06/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703928201
Principal investigator 1 Boehringer Ingelheim International GmbH $118.00 12/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703928009
Principal investigator 1 Boehringer Ingelheim International GmbH $512.00 12/03/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703928621
Principal investigator 1 Boehringer Ingelheim International GmbH $20.43 12/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703925119
Principal investigator 1 Boehringer Ingelheim International GmbH $10.21 12/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703925121
Principal investigator 1 Boehringer Ingelheim International GmbH $30.64 12/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703925131
Principal investigator 1 Boehringer Ingelheim International GmbH $20.43 12/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703925135
Principal investigator 1 Boehringer Ingelheim International GmbH $1,301.00 11/22/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703923551
Principal investigator 1 Boehringer Ingelheim International GmbH $103.00 11/22/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924517
Principal investigator 1 Abbott Laboratories $75.00 11/20/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703425941
Principal investigator 1 Abbott Laboratories $75.00 11/20/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703425943
Principal investigator 1 Abbott Laboratories $37.50 11/20/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703425945
Principal investigator 1 Abbott Laboratories $62.50 11/20/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703425947
Principal investigator 1 Abbott Laboratories $75.00 11/20/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703425949
Principal investigator 1 Abbott Laboratories $275.00 11/20/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703425951
Principal investigator 1 Abbott Laboratories $37.50 11/20/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703425953
Principal investigator 1 Abbott Laboratories $75.00 11/20/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703425955
Principal investigator 1 Abbott Laboratories $62.50 11/20/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703425957
Principal investigator 1 LivaNova USA, Inc. $1,500.00 11/13/2019 Non-covered Recipient Entity
The Research Foundation of State University of New York
ANTHEM HFrEF No dispute reported 06/30/2026 703215849
Principal investigator 1 Boehringer Ingelheim International GmbH $103.00 11/01/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703924477
Principal investigator 1 Abbott Laboratories $150.00 10/31/2019 Non-covered Recipient Entity
Schulman Associates Institutional Review Board Inc
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703421759
Principal investigator 1 Boehringer Ingelheim International GmbH $256.00 10/15/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703923003
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 10/04/2019 Covered Recipient Teaching Hospital
STONY BROOK UNIVERSITY HOSPITAL
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691506139
Principal investigator 1 Boehringer Ingelheim International GmbH $1,553.00 10/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703922779
Principal investigator 1 Boehringer Ingelheim International GmbH $1,553.00 10/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703922781
Principal investigator 1 Boehringer Ingelheim International GmbH $1,465.00 10/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703922783
Principal investigator 1 Boehringer Ingelheim International GmbH $1,203.00 10/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703922785
Principal investigator 1 Boehringer Ingelheim International GmbH $256.00 10/01/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703922777
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $508.29 09/30/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 704738945
Principal investigator 1 Abbott Laboratories $1,850.00 09/26/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703420659
Principal investigator 1 Amgen Inc. $1,865.00 09/23/2019 Non-covered Recipient Entity
STONY BROOK MEDICINE
GALACTIC-HF No dispute reported 06/30/2026 675793207
Principal investigator 1 Boehringer Ingelheim International GmbH $1,096.00 09/10/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918521
Principal investigator 1 Boehringer Ingelheim International GmbH $1,004.00 09/10/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918523
Principal investigator 1 Boehringer Ingelheim International GmbH $1,096.00 09/06/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918597
Principal investigator 1 Boehringer Ingelheim International GmbH $626.00 09/06/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918599
Principal investigator 1 Boehringer Ingelheim International GmbH $10.17 09/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703921427
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,066.31 08/31/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 704738943
Principal investigator 1 LivaNova USA, Inc. $10,500.00 08/28/2019 Non-covered Recipient Entity
The Research Foundation of State University of New York
ANTHEM HFrEF No dispute reported 06/30/2026 703215847
Principal investigator 1 Boehringer Ingelheim International GmbH $103.00 08/05/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703917761
Principal investigator 1 Boehringer Ingelheim International GmbH $1,203.00 08/01/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703916847
Principal investigator 1 Boehringer Ingelheim International GmbH $1,035.00 08/01/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703917639
Principal investigator 1 LivaNova USA, Inc. $9,998.00 07/26/2019 Non-covered Recipient Entity
The Research Foundation of State University of New York
ANTHEM HFrEF No dispute reported 06/30/2026 703215985
Principal investigator 1 Abbott Laboratories $93.75 07/24/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703417257
Principal investigator 1 Boehringer Ingelheim International GmbH $640.00 07/15/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703916027
Principal investigator 1 Boehringer Ingelheim International GmbH $1,035.00 07/08/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703916029
Principal investigator 1 Boehringer Ingelheim International GmbH $103.00 07/08/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703916031
Principal investigator 1 Boehringer Ingelheim International GmbH $10.46 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703919293
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703919295
Principal investigator 1 Boehringer Ingelheim International GmbH $10.46 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703919297
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703919299
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703919301
Principal investigator 1 Boehringer Ingelheim International GmbH $80.62 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703919305
Principal investigator 1 Boehringer Ingelheim International GmbH $10.46 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703919379
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703919385
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703919389
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703919391
Principal investigator 1 Boehringer Ingelheim International GmbH $26.11 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703919397
Principal investigator 1 Boehringer Ingelheim International GmbH $26.11 07/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703926689
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,066.31 06/30/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 704738941
Principal investigator 1 Boehringer Ingelheim International GmbH $480.00 06/14/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703912975
Principal investigator 1 Boehringer Ingelheim International GmbH $1,553.00 06/12/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703912721
Principal investigator 1 Boehringer Ingelheim International GmbH $1,553.00 06/12/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703912723
Principal investigator 1 Boehringer Ingelheim International GmbH $1,465.00 06/12/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703912725
Principal investigator 1 Boehringer Ingelheim International GmbH $1,096.00 06/12/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703912727
Principal investigator 1 Boehringer Ingelheim International GmbH $20.85 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703914729
Principal investigator 1 Boehringer Ingelheim International GmbH $10.42 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703914741
Principal investigator 1 Boehringer Ingelheim International GmbH $20.85 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914839
Principal investigator 1 Boehringer Ingelheim International GmbH $26.23 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914841
Principal investigator 1 Boehringer Ingelheim International GmbH $20.85 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914845
Principal investigator 1 Boehringer Ingelheim International GmbH $20.85 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914847
Principal investigator 1 Boehringer Ingelheim International GmbH $49.53 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914849
Principal investigator 1 Boehringer Ingelheim International GmbH $5.12 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914851
Principal investigator 1 Boehringer Ingelheim International GmbH $10.42 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914933
Principal investigator 1 Boehringer Ingelheim International GmbH $20.85 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914937
Principal investigator 1 Boehringer Ingelheim International GmbH $20.85 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914941
Principal investigator 1 Boehringer Ingelheim International GmbH $20.85 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703916039
Principal investigator 1 Boehringer Ingelheim International GmbH $20.85 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703916051
Principal investigator 1 Boehringer Ingelheim International GmbH $26.23 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703916137
Principal investigator 1 Boehringer Ingelheim International GmbH $20.85 06/04/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703926125
Principal investigator 1 Abbott Laboratories $3,950.00 04/24/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703414033
Principal investigator 1 Abbott Laboratories $650.00 04/18/2019 Non-covered Recipient Entity
Schulman Associates Institutional Review Board Inc
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703413447
Principal investigator 1 Abbott Laboratories $350.00 04/04/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703414035
Principal investigator 1 Boehringer Ingelheim International GmbH $24.57 04/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703912519
Principal investigator 1 Boehringer Ingelheim International GmbH $24.57 04/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703912525
Principal investigator 1 Boehringer Ingelheim International GmbH $20.78 04/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703912529
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 04/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703913469
Principal investigator 1 Boehringer Ingelheim International GmbH $10.39 04/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703913473
Principal investigator 1 Boehringer Ingelheim International GmbH $24.57 04/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703913475
Principal investigator 1 Boehringer Ingelheim International GmbH $24.57 04/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703913483
Principal investigator 1 Boehringer Ingelheim International GmbH $47.56 04/02/2019 Non-covered Recipient Entity
STONY BROOK UNIV MEDCL CTR
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703926507
Principal investigator 1 American Regent $500.00 03/13/2019 Non-covered Recipient Entity
The Research Foundation For The Stateuniversity Of New York
Heart_FID No dispute reported 06/30/2026 681796351
Principal investigator 1 Amgen Inc. $477.84 03/08/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY HOSPITAL
GALACTIC-HF No dispute reported 06/30/2026 675793227
Principal investigator 1 Amgen Inc. $40,776.00 02/27/2019 Non-covered Recipient Entity
RESEARCH FNDTN OF STATE UNIV OF NY
GALACTIC-HF No dispute reported 06/30/2026 675790905
Principal investigator 1 Abbott Laboratories $2,825.00 02/13/2019 Non-covered Recipient Entity
University of the State of New York (University at Buffalo)
PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy No dispute reported 06/30/2026 703413111
Principal investigator 1 Amgen Inc. $3,065.64 02/11/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY HOSPITAL
GALACTIC-HF No dispute reported 06/30/2026 675793229
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 01/30/2019 Covered Recipient Teaching Hospital
STONY BROOK UNIVERSITY HOSPITAL
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691308311
Principal investigator 1 Merck Sharp & Dohme Corporation $2,171.16 01/30/2019 Covered Recipient Teaching Hospital
STONY BROOK UNIVERSITY HOSPITAL
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691310321
Principal investigator 1 Amgen Inc. $77.25 01/01/2019 Non-covered Recipient Entity
STONY BROOK MEDICINE
GALACTIC-HF No dispute reported 06/30/2026 675793203
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,910.00 01/01/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER
OBSERVATIONAL REGISTRY OF TREATMENT PATTERNS IN US HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION No dispute reported 06/30/2026 640727301